Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia

Malignant Hyperthermia Clinical Trial

— MHCZECH  

Official title:

Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia (MH): Retrospective MH Registry Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05036148
• Other study ID #: KDAR FN Brno MH
• Status: Completed
• Start date: September 1, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: April 2022
• Source: Brno University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Academic centre for Malignant Hyperthermia of Masaryk University (ACMHMU) was established in 2021 in Brno, Czech Republic and consists of four academic departments of Medical Faculty of Masaryk University in two tertiary university hospitals, University Hospital Brno and St. Anne Faculty Hospital. These departments collaborated and operated since 2002 and since 2019 is Brno one of the of centre of EMHG (www.emhg.org). Aim of this study was to describe the Czech and Slovak (CZ-SK) cohort of MHS patients, the biggest Slavonic MHS cohort known by now, and to fill the knowledge gap about the Slavonic population in perspective of MH.

Description:

We evaluated every referral to the MH centre since 2002 then. IVCT results, clinical data, personal and family history and molecular genetic data, have been recorded in an electronic medical record. Potential MHS patients, probands, were investigated according to the European Malignant Hyperthermia Group (EMHG) recommendations using IVCT and/or RYR1 and CACNA1S sequence variant screening. Each proband is a representative of one unrelated family. As the diagnostic guidelines were changing in the time, so was our diagnostic algorithm with the development of new knowledge and methods.

Originally before 2015, for each proband or the nearest relative in case that the index case could not be tested, MH must be confirmed/excluded by IVCT. Only with a positive IVCT positive result (MHS, MHEh, MHEc), genetic diagnosis was originated.

iIn 2015, a new EMHG guideline for the diagnosis of MH was issued and significantly moved the DNA diagnosis of MH to the forefront and we started to use genetic testing as a first diagnostic step. Not finding the diagnostic variant does not exclude MH susceptibility and IVCT needs to follow for final diagnosis. IVCT has been providing according to the best practise and EMGH guidelines.

So far, the genetic diagnosis of MH in the Czech Republic has been in several stages - starting with standard scoring of 33 most common causal diagnostic variants of the RYR1 gene by using multiplex ligation-dependent probe amplification (MLPA) (SALSA MLPA probemix P281-A3/P282-A3 RYR1, MRC Holand). In case of a negative result, direct sequence analysis of the RYR1 and CACNA1S gene sections followed, where the remaining causal diagnostic variants occur. Since 2021 MLPA and direct sequencing of hot spots regions of RYR1 and CACNA1S was routinely replaced by next-generation sequencing (NGS) at the level of a panel of genes associated with neuromuscular diseases (including RYR1, CACNA1S and STAC3).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 286
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Gender: All
• Age group: 1 Month to 99 Years

Eligibility

Inclusion Criteria:

• Patients indicated to MH center for MH diagnostic

Exclusion Criteria:

• conditions clearly not related to MH, e.g. neuromuscular diseases

• syndromes without MH risk; anaesthetic complications without MH symptoms, e.g. prolongated awakening due to deficit of cholinesterase

• probands with missing data

• probands with yet not closed MH diagnostic process (waiting for genetics or IVCT, myopatic patients without MH diagnostic variant where the IVCT was not recommended because of its invasivity)

• non-compliant probands, who refused the diagnostic process.

Related Conditions & MeSH terms

• Fever
• Hyperthermia
• Malignant Hyperthermia

Intervention

Other:
• Data analysis
MH registry data will be screened for MH positive diagnosis

Locations

Country	Name	City	State
Czechia	Brno University Hospital - Academic Centre for Malignant Hyperthermia of Masaryk University Brno	Brno	South Moravian Region

Sponsors (2)

Lead Sponsor	Collaborator
Brno University Hospital	Centre of Malignant Hypertermia, Faculty of medicine, Masaryk University Brno

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of MH in our cohort of patients	Data registry will be screened for positive MH results	20 years retrospectively
Secondary	prevalence of occurrence diagnostic variants in MHS group of patients.	Data registry will be screened for different MH gene variants	20 years retrospectively
Secondary	prevalence of each found diagnostic variant in our Czech-and-Slovak cohort of patients.	Data registry will be screened for each found diagnostic variant in our Czech-and-Slovak cohort of patients.	20 years retrospectively